Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Sector Index sinking about 0.2% and shares of health care companies in the S&P 500 slipping about 0.1% as a group.
In company news, Alliqua Inc. ( ALQA ) was sharply higher in mid-day trading after the early-stage drugmaker Monday said its Biovance Human Amniotic Membrane Allograft has been approved for Medicare and Medicaid reimbursement.
The new and unique Level II product reimbursement Q code will take take effect on Jan. 1, 2015. The company's Allograft is used to repair patient wounds and is developed from human placenta following healthy, full-term pregnancies.
ALQA shares were up more than 18% this afternoon at $5.51 apiece, back down from an early run to $6.12 a share. The stock has traded within a 52-week range of $3.50 to $10.11 a share, rising more than 54% over the past 12 months through Friday's close.
In other sector news,
(+) CVD, (+25.3%) Accepts $5.6 bln buyout offer from Laboratory Corp. of America ( LH ), with CVD shareholders receiving $75.76 in cash and 0.2686 of a LH share per share - or $105.12 per share, a 31.5% premium over Friday's closing price.
(-) NYMX, (84.4-%) NX-1207 drug candidate fails to meet primary endpoint in a pair of Phase III trials of the prospective treatment for benign prostatic hyperplasia.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.